Respiratory diseases stories

Sep 8, 2026

AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.

Sep 8, 20263 sources

AstraZeneca's experimental COPD drug shows strong results in late-stage trials

AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.

Sep 8, 20268 sources

Jul 9, 2026

Moderna Wins EU Contract for RSV Vaccine Supply

Moderna has secured a contract with the European Union to supply its respiratory syncytial virus (RSV) vaccine, expanding the company's vaccine portfolio beyond COVID-19.

Jul 9, 20261 source

Top claims

▪AstraZeneca's tozorakimab is currently under priority review by the U.S. Food and Drug Administration, with regulatory approval expected in the first quarter of 2027
▪AstraZeneca CEO Pascal Soriot noted that previous industry attempts to target the IL-33 protein had limited success, leading to low initial investor expectations for tozorakimab
▪AstraZeneca's tozorakimab reduced moderate and severe COPD flare-ups by approximately 30% across the overall trial population of current and former smokers over one year

Subtopics

Drug Approval and Clinical Trials2 Pharma2 Pharmaceutical Industry2 Clinical trials1 Infectious Disease and Outbreaks1 Public healthcare1 Vaccine development1 Vaccines and Immunization Policy1

Related timelines